Andrea Wolf, MD, on Lung Cancer Rates in Women

Video

The director of the new Women’s Lung Cancer Program at Mount Sinai spoke about the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

According to recent studies, more women have died of lung cancer than the total number of women who have died from breast, ovarian and uterine cancer combined.

Moreover, women who have never smoked are suggested to be twice as likely to develop lung cancer than men who have never smoked, partially due to genetic and other factors. Women who smoke are also more likely to develop lung cancer than men, and when screened, women are almost twice as likely to be diagnosed with lung cancer.

Given these staggering statistics, Andrea Wolf, MD, and her colleagues at Mount Sinai launched the Women’s Lung Cancer Program in an attempt to address these issues in both research and screening. In an interview with CancerNetwork®, Wolf, director of the new Women’s Lung Cancer Program, discussed the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content